The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA
Open accessAbstract
This study reports on the design of mRNA and adjuvant-loaded lipid nanoparticles for therapeutic cancer vaccination. The use of nucleoside-modified mRNA has previously been shown to improve the translational capacity and safety of mRNA-therapeutics, as it prevents the induction of type I interferons (IFNs). However, type I IFNs were identified as the key molecules that trigger the activation of antigen presenting cells, and as such drive T cell immunity. We demonstrate that nucleoside-modified mRNA can be co-delivered with the clinically approved TLR agonist monophosphoryl lipid A (MPLA). As such, we simultaneously allow high antigen expression in vivo while substituting the type I IFN response by a more controllable adjuvant. This strategy shows promise to induce effective antigen-specific T cell immunity and may be useful to enhance the safety of mRNA vaccines.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several preclinical studies have indicated that an unmodified mRNA platform induces a more pronounced type-I IFN-polarized innate immune response [11,62]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [62]
In the citing paper
“In comparison, cationic mRNA LNPs composed of a cationic lipid and cholesterol, or DOPE were found to primarily target the lungs, where they transfect tissueresident DCs, macrophages and endothelial cells [142,157,158].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [157]
In the citing paper
“Comparative studies performed by our research group and others demonstrated that nucleoside-modified mRNA LNPs outperformed unmodified mRNA LNPs in translation capacity, but failed to elicit successful CTL responses due to the drastically reduced production of type I IFNs [119,157].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [157]
In the citing paper
“In a proof-of-concept study, we demonstrated that nucleoside-modified mRNA can be co-delivered with the clinically approved TLR agonist MPLA, achieving functional CTL responses like unmodified mRNA, but with strongly reduced type I IFN responses [157].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [157]
Citations
Cites
Proceedings of the National Academy of Sciences of the United States of America
Dowling, J. E., & Wald, G. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1981.tb06752.x · Cited by 17,937
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Biomolecular coronas provide the biological identity of nanosized materials
Monopoli, M. P., Åberg, C., Salvati, A., & Dawson, K. A. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.207 · Cited by 3,017
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Flagged first, then by citations
Cited by
Sorted by citations
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852
Lipid nanoparticles for nucleic acid delivery: Current perspectives
Samaridou, E., Heyes, J. A., & Lutwyche, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.002 · Cited by 609
The dawn of mRNA vaccines: the COVID-19 case
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.043 · Cited by 504
Self-citationTailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response
Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.002 · Cited by 376
Three decades of messenger RNA vaccine development
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342
Self-citationAdvances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy
Guevara, M. L., Persano, F., & Persano, S. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.589959 · Cited by 261
Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects
Kiaie, S. H., Zolbanin, N. M., Ahmadi, A., Bagherifar, R., Valizadeh, H., Kashanchi, F., & Jafari, R. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01478-7 · Cited by 269
Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines
Aldosari, B. N., Alfagih, I. M., & Almurshedi, A. S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020206 · Cited by 248
Lindsay, K. E., Bhosle, S. M., Zurla, C., Beyersdorf, J., Rogers, K. A., Vanover, D., Xiao, P., Araínga, M., Shirreff, L. M., Pitard, B., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0378-3 · Cited by 218
Islam, M. A., Jamie, R., Reesor, E., Zope, H. R., Tao, W., Lim, M., Ding, J., Chen, Y., Aduluso, D., Zetter, B. R., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120431 · Cited by 220
Emerging Nano‐/Microapproaches for Cancer Immunotherapy
Mi, Y., Hagan, C. T., Vincent, B. G., & Wang, A. Z. (2019) · Advanced Science · doi:10.1002/advs.201801847 · Cited by 178
Lou, G., Anderluzzi, G., Schmidt, S., Woods, S., Gallorini, S., Brazzoli, M., Giusti, F., Ferlenghi, I., Johnson, R. N., Roberts, C. W., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.027 · Cited by 176
Nanoscale platforms for messenger RNA delivery
Li, B., Zhang, X., & Dong, Y. (2019) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1530 · Cited by 170
Liu, J., Zhang, R., & Xu, Z. P. (2019) · Small · doi:10.1002/smll.201900262 · Cited by 161
Minnaert, A.-K., Vanluchene, H., Verbeke, R., Lentacker, I., De Smedt, S. C., Raemdonck, K., Sanders, N. N., & Remaut, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113900 · Cited by 157
Self-citationNanomedicine-Based Approaches for mRNA Delivery
Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139
Recent Advances in Cell Membrane‐Derived Biomimetic Nanotechnology for Cancer Immunotherapy
Raza, F., Zafar, H., Zhang, S., Kamal, Z., Su, J., Yuan, W., & Mingfeng, Q. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002081 · Cited by 135
Nanoplatforms for mRNA Therapeutics
Meng, C., Chen, Z., Li, G., Welte, T., & Shen, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000099 · Cited by 130
Yang, J., Tseng, J., Yu, G., Luo, Y., Huang, C. F., Hong, Y., & Chuang, T. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020423 · Cited by 129
Liu, D., Liang, S., Ma, K., Meng, Q., Li, X., Wei, J. Q., Zhou, M., Yun, K., Pan, Y., Rao, L., et al. (2023) · Advanced Materials · doi:10.1002/adma.202304845 · Cited by 126
mRNA therapeutics deliver a hopeful message
Zhong, Z., Cafferty, S. M., Combes, F., Huysmans, H., Temmerman, J. D., Gitsels, A., Vanrompay, D. C. G., Catani, J. P., & Sanders, N. N. (2018) · Nano Today · doi:10.1016/j.nantod.2018.10.005 · Cited by 124
From structural design to delivery: mRNA therapeutics for cancer immunotherapy
Zhou, F., Huang, L., Li, S., Yang, W., Chen, F., Cai, Z., Liu, X., Xu, W., Lehto, V., Lächelt, U., et al. (2023) · Exploration · doi:10.1002/exp.20210146 · Cited by 117
Recent Advancements in Nanomedicine for ‘Cold’ Tumor Immunotherapy
Chen, Q., Sun, T., & Jiang, C. (2021) · Nano-Micro Letters · doi:10.1007/s40820-021-00622-6 · Cited by 115
mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond
Sentí, M. E., del Valle, L. G., & Schiffelers, R. M. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115190 · Cited by 124
Nanoparticles for Immune Stimulation Against Infection, Cancer, and Autoimmunity
Singha, S., Shao, K., Ellestad, K. K., Yang, Y., & Santamaría, P. (2018) · ACS Nano · doi:10.1021/acsnano.8b05950 · Cited by 114
Esprit, A., de Mey, W., Shahi, R. B., Thielemans, K., Franceschini, L., & Breckpot, K. (2020) · Vaccines · doi:10.3390/vaccines8040776 · Cited by 112
Self-citationTargeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors
Anthiya, S., Öztürk, S. C., Yanık, H., Tavukçuoğlu, E., Şahin, A., Datta, D., Charissé, K., Moreira, D., Loza, M. I., Calvo, A., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.016 · Cited by 102
Zhang, R., Tang, L., Tian, Y., Xiao, J., Hu, Q., Zhou, B., Ding, Z., Xu, H., & Yang, L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.023 · Cited by 101
Lipid Nanoparticles for Delivery of Therapeutic RNA Oligonucleotides
Moss, K. H., Popova, P. G., Hadrup, S. R., Astakhova, K., & Taskova, M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01290 · Cited by 101
Pan, L., Zhang, L., Deng, W., Lou, J., Gao, X., Lou, X., Liu, Y., Yao, X., Sheng, Y., Yan, Y., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.041 · Cited by 100
Lin, G., Revia, R. A., & Zhang, M. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202007096 · Cited by 97
Lou, B., Koker, S. D., Lau, C. Y. J., Hennink, W. E., & Mastrobattista, E. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00524 · Cited by 92
Li, X., Qi, J., Wang, J., Hu, W., Zhou, W., Wang, Y., & Li, T. (2024) · Theranostics · doi:10.7150/thno.84291 · Cited by 100
Cell-Penetrating Peptides: Emerging Tools for mRNA Delivery
Yokoo, H., Oba, M., & Uchida, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010078 · Cited by 88
Li, Y., Ayala‐Orozco, C., Rauta, P. R., & Krishnan, S. (2019) · Nanoscale · doi:10.1039/c9nr05371a · Cited by 84
Hybrid nanovaccine for the co-delivery of the mRNA antigen and adjuvant
Yang, J., Arya, S., Lung, P., Lin, Q., Huang, J., & Li, Q. (2019) · Nanoscale · doi:10.1039/c9nr05475h · Cited by 85
Verbeke, R., Lentacker, I., Breckpot, K., Janssens, J., Calenbergh, S. V., Smedt, S. C. D., & Dewitte, H. (2019) · ACS Nano · doi:10.1021/acsnano.8b07660 · Cited by 85
Self-citationNano-immunotherapy: Overcoming tumour immune evasion
Guevara, M. L., Persano, F., & Persano, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.010 · Cited by 83
mRNA vaccines: the most recent clinical applications of synthetic mRNA
Kwon, S., Kwon, M., Im, S., Lee, K., & Lee, H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01381-7 · Cited by 85
Kim, S., Jeon, J. H., Kim, M., Lee, Y., Hwang, Y.-H., Park, M., Li, C. H., Lee, T., Lee, J.-A., Kim, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51411-9 · Cited by 78
Tran, T. H., Tran, T. T. P., Truong, D. H., Nguyen, H. T., Pham, T. T., Yong, C. S., & Kim, J. O. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.05.043 · Cited by 69
A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs
Bogaert, B., Sauvage, F., Guagliardo, R., Muntean, C., Nguyen, V. P., Pottie, E., Wels, M., Minnaert, A., Rycke, R. M. D., Yang, Q., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.009 · Cited by 69
Devoldere, J., Peynshaert, K., Dewitte, H., Vanhove, C., Groef, L. D., Moons, L., Özcan, S. Y., Dalkara, D., Smedt, S. C. D., & Remaut, K. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.042 · Cited by 70
Self-citationDelivery of mRNA for regulating functions of immune cells
Shi, J. Y., Huang, M., Lu, Z.-D., Du, X., Shen, S., Xu, C., & Wang, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.033 · Cited by 62
Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy
Yoo, Y. J., Lee, C. H., Park, S. H., & Lim, Y. T. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.047 · Cited by 62
Wang, F., Xiao, W., Elbahnasawy, M. A., Bao, X., Zheng, Q., Gong, L., Zhou, Y., Yang, S., Fang, A., Farag, M. M. S., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00980 · Cited by 59
A polyphenol-assisted IL-10 mRNA delivery system for ulcerative colitis
Chen, Z., Hao, W., Gao, C., Zhou, Y. Y., Zhang, C., Zhang, J., Wang, R., Wang, Y., & Wang, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.025 · Cited by 58
mRNA, a Revolution in Biomedicine
Baptista, B., Carapito, R., Laroui, N., Pichon, C., & de Sousa, F. P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122090 · Cited by 61
Nonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy
Wang, Y., Zhang, R., Tang, L., & Li, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030512 · Cited by 58
Application of lipid-based nanoparticles in cancer immunotherapy
Zhang, Z., Yao, S., Hu, Y., Zhao, X. B., & Lee, R. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.967505 · Cited by 58
RNA cancer nanomedicine: nanotechnology-mediated RNA therapy
Ferdows, B. E., Patel, D. N., Chen, W., Huang, X., Kong, N., & Tao, W. (2022) · Nanoscale · doi:10.1039/d1nr06991h · Cited by 59
Lipid-Based Vectors for Therapeutic mRNA-Based Anti-Cancer Vaccines
Guevara, M. L., Persano, S., & Persano, F. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190619150221 · Cited by 57
mRNA vaccine designs for optimal adjuvanticity and delivery
Mochida, Y., & Uchida, S. (2024) · RNA Biology · doi:10.1080/15476286.2024.2333123 · Cited by 57
mRNA vaccines contribute to innate and adaptive immunity to enhance immune response in vivo
Cao, Q., Fang, H., & Tian, H. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122628 · Cited by 56
Nanotechnology-based products for cancer immunotherapy
Shams, F., Golchin, A., Azari, A., Amirabad, L. M., Zarein, F., Khosravi, A., & Ardeshirylajimi, A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06876-y · Cited by 56
Targeting strategies for mRNA delivery
Meyer, R. A., Neshat, S. Y., Green, J. J., Santos, J. L., & Tuesca, A. D. (2022) · Materials Today Advances · doi:10.1016/j.mtadv.2022.100240 · Cited by 55
Harnessing Engineered Immune Cells and Bacteria as Drug Carriers for Cancer Immunotherapy
Jiang, J., Huang, Y., Zeng, Z., & Zhao, C. (2023) · ACS Nano · doi:10.1021/acsnano.2c07607 · Cited by 53
Clinical translation of gene medicine
Wang, F., Qin, Z., Lu, H., He, S., Luo, J. C., Jin, C., & Song, X. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3108 · Cited by 48
Hoecke, L. V., Verbeke, R., Vlieger, D. D., Dewitte, H., Roose, K., Nevel, S. V., Krysko, O., Bachert, C., Schepens, B., Lentacker, I., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.04.015 · Cited by 46
Self-citationHNF4α in Hepatocyte Health and Disease
Kotulkar, M., Robarts, D. R., & Apte, U. M. (2023) · Seminars in Liver Disease · doi:10.1055/a-2097-0660 · Cited by 44
Nanoscale delivery platforms for RNA therapeutics: Challenges and the current state of the art
Rhym, L. H., & Anderson, D. G. (2022) · Med · doi:10.1016/j.medj.2022.02.001 · Cited by 45
Gene delivery for immunoengineering
Neshat, S. Y., Tzeng, S. Y., & Green, J. J. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.05.008 · Cited by 44
Thangam, R., Patel, K. D., Kang, H., & Paulmurugan, R. (2021) · Vaccines · doi:10.3390/vaccines9080935 · Cited by 44
Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications
Salah, A., Wang, H., Li, Y., Ji, M., Ou, W., Qi, N., & Wu, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.686544 · Cited by 44
Rational nanocarrier design towards clinical translation of cancer nanotherapy
Guo, D., Ji, X., & Luo, J. (2021) · Biomedical Materials · doi:10.1088/1748-605x/abe35a · Cited by 39
Promising RNA-based cancer gene therapy using extracellular vesicles for drug delivery
Xue, V. W., Wong, S. C. C., Song, G., & Cho, W. C. S. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1738377 · Cited by 37
Nanomedicine for advanced cancer immunotherapy
Diep, Y. N., Kim, T. J., Cho, H., & Lee, L. P. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.004 · Cited by 35
Jiang, Q., Yuan, Y., Gong, Y., Luo, X., Su, X., Hu, X., & Zhu, W. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03051-6 · Cited by 35
mRNA delivery via non-viral carriers for biomedical applications
Shuai, Q., Zhu, F., Zhao, M., & Yan, Y. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121020 · Cited by 35
Wu, Y., Liang, X., Mao, C., & Jiang, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c07632 · Cited by 34
Zwitterionic materials for nucleic acid delivery and therapeutic applications
He, S., & Liu, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.017 · Cited by 33
Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines
Abbasi, S., & Uchida, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050644 · Cited by 33
In Vitro Transcribed mRNA Vaccines with Programmable Stimulation of Innate Immunity
Loomis, K. H., Lindsay, K. E., Zurla, C., Bhosle, S. M., Vanover, D. A., Blanchard, E. L., Kirschman, J. L., Bellamkonda, R. V., & Santangelo, P. J. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00443 · Cited by 32
Immunomodulatory and immune-toxicological role of nanoparticles: Potential therapeutic applications
Sau, S., Dey, A., Pal, P., Das, B., Maity, K. K., Maity, K. K., Dash, S. K., & Das, B. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112251 · Cited by 31
The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road
Goyvaerts, C., & Breckpot, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02052 · Cited by 27
Self-citationLipid nanoparticles: a promising tool for nucleic acid delivery in cancer immunotherapy
Abaza, T., Mohamed, E., & Zaky, M. Y. (2025) · Medical Oncology · doi:10.1007/s12032-025-02939-3 · Cited by 35
Noninvasive imaging in cancer immunotherapy: The way to precision medicine
Du, Y., Qi, Y., Jin, Z., & Tian, J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.08.009 · Cited by 30
Magaña, J. R., Guerra‐Rebollo, M., Borrós, S., & Fornaguera, C. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01585-y · Cited by 28
The landscape of neoantigens and its clinical applications: From immunobiology to cancer vaccines
Chakraborty, C., Majumder, A., Bhattacharya, M., Chatterjee, S., & Lee, S. (2024) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2024.100177 · Cited by 29
Advancing mRNA technologies for therapies and vaccines: An African context
Kairuz, D., Samudh, N., Ely, A., Arbuthnot, P., & Bloom, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018961 · Cited by 25
Chung, S., Lee, C. M., & Zhang, M. (2022) · Nanoscale Horizons · doi:10.1039/d2nh00289b · Cited by 28
Ding, X., Jia, X., Yuan, H., Pang, D., Zhao, H.-L., Sun, P., Liu, F., Chao, D., Xin, M., Wang, C., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu1647 · Cited by 26
Co-Delivery of mRNA and pDNA Using Thermally Stabilized Coacervate-Based Core-Shell Nanosystems
Nasr, S. S., Lee, S., Thiyagarajan, D., Boese, A. S., Loretz, B., & Lehr, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111924 · Cited by 22
Nanomedicine for the Delivery of RNA in Cancer
Ghidini, M., Silva, S. G., Evangelista, J., Vale, M. L. C., Farooqı, A. A., & Pinheiro, M. (2022) · Cancers · doi:10.3390/cancers14112677 · Cited by 23
Cancer mRNA vaccines: clinical application progress and challenges
Li, H., Min, L., Du, H., Wei, X., & Tong, A. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217752 · Cited by 26
Physical transfection technologies for macrophages and dendritic cells in immunotherapy
Harizaj, A., Smedt, S. C. D., Lentacker, I., & Braeckmans, K. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1828340 · Cited by 21
Self-citationOff the beaten path: Novel mRNA-nanoformulations for therapeutic vaccination against HIV
D’haese, S., Lacroix, C., García, F., Plana, M., Ruță, S. M., Vanham, G. L., Verrier, B., & Aerts, J. L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.009 · Cited by 18
Carbon Nanomaterials: Emerging Roles in Immuno-Oncology
Patrick, B., Akhtar, T., Kousar, R., Huang, C., & Li, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076600 · Cited by 21
Tafaleng, E. N., Mukherjee, A., Bell, A. W., Morita, K., Guzman‐Lepe, J., Haep, N., Florentino, R. M., Díaz‐Aragon, R., Frau, C., Ostrowska, A., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1763 · Cited by 16
Yang, S., Ta, Y. N., & Chen, Y. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01908-7 · Cited by 16
Cancer vaccines: Discovery, development, and challenges for clinical translation
Zhang, Z., Yao, S., Wang, Y., Luo, K., Amiji, M. M., & Anderson, K. C. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123615 · Cited by 15
In Situ Chimeric Antigen Receptor Macrophage Therapy via Co-Delivery of mRNA and Immunostimulant
Han, J., Fagan, E., Yeom, K., & Park, J. (2025) · ACS Nano · doi:10.1021/acsnano.5c09138 · Cited by 15
Effective mRNA Delivery by Condensation with Cationic Nanogels Incorporated into Liposomes
Duskunovic, N., Im, S. H., Lee, J. H., & Chung, H. J. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00089 · Cited by 14
Advances in liposome-based delivery of RNA therapeutics for cancer treatment
Sanati, M., Afshari, A. R., Ahmadi, S. S., Kesharwani, P., & Sahebkar, A. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.010 · Cited by 14
Advances and Strategies in Enhancing mRNA Cancer Vaccines
Zhang, M., Chen, S., Hu, H.-J., Ong, Y., & Ni, Q. (2025) · Advanced Materials · doi:10.1002/adma.202509880 · Cited by 16
Considerations on the Design of Lipid-based mRNA Vaccines Against Cancer
Meulewaeter, S., Zhang, Y., Wadhwa, A., Fox, K., Lentacker, I., Harder, K. W., Cullis, P. R., Smedt, S. C. D., Cheng, M. H. Y., & Verbeke, R. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168385 · Cited by 13
Self-citationSchievelbein, M., Resende, C., Glennon, M. M., Kerosky, M., & Brown, J. A. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105548 · Cited by 12
Mimicking Pathogens to Augment the Potency of Liposomal Cancer Vaccines
Twilhaar, M. K. N., Czentner, L., van Nostrum, C. F., Storm, G., & den Haan, J. M. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13070954 · Cited by 13
mRNA-LNP vaccine strategies: Effects of adjuvants on non-parenchymal liver cells and tolerance
Svensson, M., Limeres, M. J., Zeyn, Y., Gambaro, R. C., Islan, G. A., Berti, I. R., Ghazi, S. F.-E., Pretsch, L., Hilbert, K., Schneider, P. M., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101427 · Cited by 10
Metadata
- Authors
- Verbeke, R., Lentacker, I., Wayteck, L., Breckpot, K., Van Bockstal, M., Descamps, B., Vanhove, C., De Smedt, S. C., & Dewitte, H.
- Affiliations
- Ghent University Hospital (BE)
- Vrije Universiteit Brussel (BE)
- Ghent University (BE)
- ORCID
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 266
- Pages
- 287-300
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2762387202
- Cited by
- 132
- References
- 66
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 15 · 2023: 14 · 2022: 20 · 2021: 20 · 2020: 16 · 2019: 17 · 2018: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- Journal of Controlled Release (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- FWO (G016513N, G0B2814N)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- nucleoside-modified mRNA, TLR agonists, monophosphoryl lipid A, lipid nanoparticles, cancer immunotherapy, mRNA vaccines, type I interferon, adjuvants, antigen-presenting cells, T cell immunity
- MeSH terms
- Animals, Cytidine, Dendritic Cells, Female, Immunotherapy, Lipid A, Lipids, Mice, Inbred C57BL, Neoplasms, RNA, Messenger, Cancer Vaccines, Toll-Like Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
